A federal judge sentenced the owner of a peptide company to nearly six years in prison for building a fraudulent business by deceiving customers and selling steroid-adulterated products. Matthew Kawa, who headed Paradigm Peptides, pleaded guilty to selling unapproved drugs and illegal imports from abroad. This sentencing is an uncommon criminal penalty in the largely unregulated peptide marketplace, often a source for those seeking health improvements outside established medical channels.
“You focused on what you wanted to build instead of thinking about the people,” stated U.S. District Court Judge Cristal Brisco. Kawa received a 70-month sentence and was ordered to forfeit $5 million in business proceeds. Kawa admitted that Paradigm’s customers trusted false claims about the company’s products. He expressed remorse, stating, “I’m deeply sorry I betrayed that trust. I should have asked harder questions and made sure what we did followed the law.” Paradigm Peptides shut down in March 2024 after it was found to fabricate its American-made claims and product purity certifications.
Paradigm imported products from countries such as China and India. Kawa admitted to altering lab certificates, and testing revealed six compounds intended to mimic testosterone all contained the actual hormone, which is strictly regulated.
Jennifer Stechkober, Kawa’s sister and main employee, received a 16-month sentence for her involvement. “These individuals are taken out of circulation,” remarked Adam Mildred, U.S. attorney for the Northern District of Indiana. Prosecutors estimated Paradigm had over 54,000 customers in the U.S. and 80 other countries.
Peptides, amino acid chains that prompt the body to perform functions such as energy storage or hormone release, have become popular for weight loss or muscle gain. Despite FDA disapproval, they entered mainstream usage. This case highlights the risk of ongoing misuse of compounds labeled “for research use only.”
Besides peptides, Paradigm pushed SARMs (selective androgen receptor modulators). Although marketed as safe dietary supplements, these products entailed serious side effects like increased heart attack risks and psychosis, warned the FDA.
Dan Murphy, a 32-year-old marketing consultant, began using Paradigm’s SARMs in 2023. He initially experienced an energy increase he appreciated. However, long-term consumption led to sleep issues, paranoia, and extreme acne. His experience culminated in receiving a letter from the Department of Justice about Paradigm’s investigation. Lab tests indicated his SARMs contained testosterone, sparking clarity over his adverse symptoms. Subsequently, a medical expert diagnosed him with “steroid-induced psychosis.”
Despite Paradigm’s closure, similar sites have emerged. Legal opinions suggest this court result might not deter the wider industry. Robert F. Kennedy Jr., the nation’s top health official, has publicly supported broader peptide accessibility. Former FDA lawyer George Karavetsos remarked that prosecuting such cases resembles “a game of whack-a-mole.” New websites, such as paradigmpeptides.is, continue selling similar products with disclaimers regarding no affiliation with Kawa’s business, expressing willingness to adjust branding if needed.